Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Neal B, et al. Among authors: meininger g. Am Heart J. 2013 Aug;166(2):217-223.e11. doi: 10.1016/j.ahj.2013.05.007. Epub 2013 Jun 24. Am Heart J. 2013. PMID: 23895803 Free article. Clinical Trial.
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group. Neal B, et al. Among authors: meininger g. Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2. Diabetes Care. 2015. PMID: 25468945 Clinical Trial.
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group. Neal B, et al. Among authors: meininger g. Diabetes Obes Metab. 2017 Mar;19(3):387-393. doi: 10.1111/dom.12829. Epub 2017 Jan 25. Diabetes Obes Metab. 2017. PMID: 28120497 Free PMC article. Clinical Trial.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. Among authors: meininger g. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group. Fulcher G, et al. Among authors: meininger g. Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8. Diabetes Obes Metab. 2016. PMID: 26450639 Clinical Trial.
Renal effects of canagliflozin in type 2 diabetes mellitus.
Perkovic V, Jardine M, Vijapurkar U, Meininger G. Perkovic V, et al. Among authors: meininger g. Curr Med Res Opin. 2015 Dec;31(12):2219-31. doi: 10.1185/03007995.2015.1092128. Epub 2015 Oct 23. Curr Med Res Opin. 2015. PMID: 26494163 Review.
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B. Fulcher G, et al. Among authors: meininger g. Diabetes Ther. 2015 Sep;6(3):289-302. doi: 10.1007/s13300-015-0117-z. Epub 2015 Jun 17. Diabetes Ther. 2015. PMID: 26081793 Free PMC article.
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. Rosenthal N, et al. Among authors: meininger g. Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Epub 2015 Aug 25. Ann N Y Acad Sci. 2015. PMID: 26305874 Review.
249 results